SARS-CoV-2: biobanking and research

The lung disease Covid-19, which is caused by the novel coronavirus SARS-CoV-2, is making the world hold its breath. To enable biomedical researchers to use biosamples effectively, the German Biobank Node (GBN) advocates a coordinated approach to the nationwide collection of SARS-CoV-2 samples. You can find information on the handling of these samples here.

Dear biobank colleagues,

please contact us if you already collect SARS-CoV-2 samples or plan to do so. If you are already collecting, please let us know,

  • how many samples are currently available in your biobank
  • which sample types (smears, serum, plasma, whole blood, etc.) are involved
  • whether the samples are processed in your biobank
  • and what data you collect in the process.

Dear colleagues from research,

our aim is to support you in the best possible way - therefore please let us know,

  • what types of samples you need,
  • whether and what types of controls you need
  • and which methods or analyses you want to conduct (cell cultures, genetic analyses, histology, etc.).

Send us this information (or your general request) by e-mail to Thank you for supporting research and biobanking on SARS-CoV-2/Covid-19!



Funding institution


COVID-19 project funding

Deutsche Herzstiftung20 April 2020 (6 p.m.)

Funding announcement for research on COVID-19 in the wake of the Sars-CoV-2 outbreak

Federal Ministry of Education and Research (BMBF)

11 May 2020

Call for Multidisciplinary Research into Epidemics and Pandemics in Response to the Outbreak of SARS-CoV-2

German Research Foundation (DFG)

1 July 2020 (letter of intent), 1. September 2020 (proposal)

You can find more information on this topic in our website section "Covid-19".


Tel. +49. 30. 450 536 347

Fax +49. 30. 450 753 69 38

Biobank Directory European Biobank Directory GBN products Download templates, manuals and other materials